Anna Sommerfeld
Anna Sommerfeld is a molecular biologist by training and has more than 25 years of experience in the pharmaceutical industry, including roles at AstraZeneca, Roche and Gilead Sciences. As the founder of Mealsizer®, she has spent the past 15 years working closely with both obesity and eating disorder care, translating research into practical solutions for better health.
.webp)
The Yazen Model - Modern Obesity Treatment Given Via a Digital Care Model. A Descriptive Analysis
The Yazen Model goes beyond traditional methods, providing patients with the tools to manage their disease, addressing medical and behavioural aspects, education and social support via a digital platform for accessible, continuous and effective weight loss and management.
Examining the effectiveness of a new digital care model on weight loss for people living with obesity
This real-world evaluation of more than 2,600 patients in Sweden showed that Yazen’s comprehensive digital obesity care model achieved 12.6% weight loss after 6 months, alongside significant improvements in cardiometabolic health markers. The model combines GLP-1 treatment, lifestyle intervention, and continuous multidisciplinary support through a digital platform designed for long-term obesity care.
